tiprankstipranks
Advertisement
Advertisement

CTOR Stock Latest News

Citius Oncology registers to sell 32.93M shares of common stock for holders
The FlyCitius Oncology registers to sell 32.93M shares of common stock for holders
2d ago
CTOR
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
5d ago
CTOR
Citius Oncology Secures New Financing to Support LYMPHIR
PremiumCompany Announcements
Citius Oncology Secures New Financing to Support LYMPHIR
26d ago
8K
CTOR
Citius Oncology Begins First European Expansion of LYMPHIR
PremiumCompany Announcements
Citius Oncology Begins First European Expansion of LYMPHIR
1M ago
8K
CTOR
Citius Oncology announces initial shipment of LYMPHIR to Europe
PremiumThe Fly
Citius Oncology announces initial shipment of LYMPHIR to Europe
1M ago
CTOR
CTXR
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
PremiumCompany AnnouncementsCitius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
1M ago
8K
CTOR
Citius Oncology highlights early LYMPHIR commercial traction, expansion
Premium
Company Announcements
Citius Oncology highlights early LYMPHIR commercial traction, expansion
2M ago
8K
CTOR
Citius Oncology provides commercial update on lymphir launch
Premium
The Fly
Citius Oncology provides commercial update on lymphir launch
2M ago
CTOR
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
PremiumCompany Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
3M ago
8K
CTOR
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
PremiumThe Fly
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
3M ago
CTOR
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
PremiumCompany Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
3M ago
8K
CTOR
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
PremiumThe Fly
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
3M ago
CTOR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
PremiumThe FlyCitius Oncology reports Q1 EPS (6c) vs. (9c) last year
4M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
Premium
The Fly
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
4M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
Premium
The Fly
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
4M ago
CTOR
CTXR
CTOR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CTOR Earnings this Week: How Will it Perform?
4M ago
CTOR
Citius files to sell shares of common stock underlying warrants for holders
PremiumThe Fly
Citius files to sell shares of common stock underlying warrants for holders
5M ago
CTOR
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
PremiumCompany Announcements
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
5M ago
CTOR
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
PremiumThe Fly
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
5M ago
CTOR
Citius Oncology Raises $18M Through Direct Offering
PremiumCompany AnnouncementsCitius Oncology Raises $18M Through Direct Offering
6M ago
8K
CTOR
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
Premium
The Fly
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
6M ago
CTOR
CTXR
Citius Oncology expands Lymphir distribution to Turkey and Middle East
Premium
The Fly
Citius Oncology expands Lymphir distribution to Turkey and Middle East
6M ago
CTOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >